Patents by Inventor Glenn Dorin
Glenn Dorin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120040396Abstract: Methods and systems for purifying bio-organic compounds are described. In certain embodiments, the methods comprise the steps of (a) providing a composition or an emulsion comprising a surfactant, host cells, an aqueous medium and a bio-organic compound produced by the host cells, wherein the solubility of the surfactant in the aqueous medium decreases with increasing temperature and wherein the temperature of the composition or emulsion is at least about 1° C. below a phase inversion temperature of the composition or emulsion; (b) raising the temperature of the composition or emulsion to at least about 1° C. above the phase inversion temperature; and (c) performing a liquid/liquid separation of the composition to provide a crude bio-organic composition or emulsion.Type: ApplicationFiled: August 5, 2011Publication date: February 16, 2012Applicant: Amyris, Inc.Inventors: Pinar Tabur, Glenn Dorin
-
Patent number: 7851433Abstract: Highly purified preparations of TFPI or TFPI analogs can be prepared using a method that generally involves the following steps: (1) expression of TFPI or TFPI analog in E. coli, (2) isolation of refractile bodies, (3) dissolution of the refractile bodies and refolding of the expressed TFPI or TFPI analog, (4) SP-Sepharose fast flow (FF) chromatography, (5) a first concentration and diafiltration step, (6) Q-Sepharose high (HP) performance chromatography, (7) butyl hydrophobic interaction chromatography (HIC), (8) SP-Sepharose HP chromatography, and (9) a second concentration/diafiltration step. Less than about 12% of the TFPI or TFPI analog molecules in such preparations are modified TFPI or TFPI analog species (i.e., oxidized, carbamylated, acetylated, deamidated, aggregated, or misfolded species).Type: GrantFiled: January 8, 2004Date of Patent: December 14, 2010Assignees: Novartis Vaccines and Diagnostics, Inc., Pharmacia & Upjohn CompanyInventors: David H. Reifsnyder, Duane Inlow, Glenn Dorin, Patricio T. Riquelme, Cynthia A. Cowgill, Douglas G. Bolesch, Mark E. Gustafson
-
Patent number: 7193042Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.Type: GrantFiled: June 7, 1995Date of Patent: March 20, 2007Assignees: Chiron Corporation, Cephalon, Inc.Inventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D. Kudrna, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
-
Patent number: 7071313Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.Type: GrantFiled: May 2, 2000Date of Patent: July 4, 2006Assignees: Cephalon, Inc., Chiron CorporationInventors: Cynthia Cowgill, Luis Juarbe-Osorio, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D Kudrna, Asuman G. Ozturk, Carl Scandella, Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
-
Publication number: 20060128947Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.Type: ApplicationFiled: January 24, 2006Publication date: June 15, 2006Applicants: Chiron Corporation, G. D. Searle & Co.Inventors: Glenn Dorin, Bo Arve, Gregory Pattison, Robert Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan Rana, Maninder Hora, Hassan Madani, Michael Tsang, Mark Gustafson, Gary Bild, Gary Johnson
-
Publication number: 20050037475Abstract: Highly purified preparations of TFPI or TFPI analogs can be prepared using a method that generally involves the following steps: (1) expression of TFPI or TFPI analog in E. coli, (2) isolation of refractile bodies, (3) dissolution of the refractile bodies and refolding of the expressed TFPI or TFPI analog, (4) SP-Sepharose fast flow (FF) chromatography, (5) a first concentration and diafiltration step, (6) Q-Sepharose high (HP) performance chromatography, (7) butyl hydrophobic interaction chromatography (HIC), (8) SP-Sepharose HP chromatography, and (9) a second concentration/diafiltration step. Less than about 12% of the TFPI or TFPI analog molecules in such preparations are modified TFPI or TFPI analog species (i.e., oxidized, carbamylated, acetylated, deamidated, aggregated, or misfolded species).Type: ApplicationFiled: January 8, 2004Publication date: February 17, 2005Applicants: Chiron Corporation, Pharmacia & Upjohn CompanyInventors: David Reifsnyder, Duane Inlow, Glenn Dorin, Patricio Riquelme, Cynthia Cowgill, Douglas Bolesch, Mark Gustafson
-
Patent number: 6756484Abstract: Disclosed is an improved process for obtaining purified, monomeric, intact, correctly-folded insulin-like growth factor-I (also known as somatomedin-C). The improvements, consisting primarily of the addition of an IGF-I unfolding/refolding step and the substitution of a reverse phase chromatography step for a gel filtration chromatography step result in a three-fold increase in final yield. The process includes the following steps, in order: first cation exchange, unfolding/refolding, hydrophobic interaction chromatography, second cation exchange, and reverse phase chromatography.Type: GrantFiled: July 12, 2000Date of Patent: June 29, 2004Assignees: Cephalon, Inc., Chiron CorporationInventors: Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka, Cynthia Cowgill, Luis G. Juarbe-Osorio, Patricio Riquelme, Glenn Dorin
-
Patent number: 6117983Abstract: Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains.Type: GrantFiled: December 15, 1997Date of Patent: September 12, 2000Assignee: Chiron CorporationInventors: Cynthia Cowgill, Louis Juarbe, Patricio Riquelme, Glenn Dorin, Christopher M. Bussineau, Robert D. Kudrna, Ausman G. Otzurk
-
Patent number: 6033875Abstract: The present invention relates to a method of making a recombinant protein in high yields by adding alkali to a cell culture that is capable of producing recombinant protein. The recombinant protein can be any protein that is suitable to be made by recombinant techniques, such as IGF.Type: GrantFiled: January 24, 1997Date of Patent: March 7, 2000Assignee: Chiron CorporationInventors: Christopher M. Bussineau, Glenn Dorin, Robert D. Kudrna
-
Patent number: 5814485Abstract: Methods for the production of interferon-.beta. polypeptides by bacterial cells, by culturing cells capable of producing IFN-.beta. polypeptide under conditions that induce increased production of IFN-.beta. polypeptide. Such conditions include, for example, low potassium cation concentration and/or very low sodium cation concentration and/or specific pH ranges.Type: GrantFiled: June 6, 1995Date of Patent: September 29, 1998Assignee: Chiron CorporationInventors: Glenn Dorin, Patrick J. McAlary, Kathleen M. Wong
-
Patent number: 5466781Abstract: A process is described for producing M-CSF from bacteria. It includes: fermentation of bacteria containing M-CSF DNA; harvest of the fractions that contain the M-CSF protein (refractile bodies); primary recovery of the protein; solubilization and denaturation of refractile bodies; M-CSF refolding; purification by column chromatography and other methods; and formulation of the properly refolded M-CSF. This method is advantageous over prior methods in terms of yield and purity.Type: GrantFiled: March 8, 1993Date of Patent: November 14, 1995Assignee: Chiron TherapeuticsInventors: Glenn Dorin, David R. Gray, Byeong S. Chang, Cynthia A. Cowgill, Robert J. Milley
-
Patent number: 5248769Abstract: A refractile material containing a heterologous protein is recovered from a host microorganism cell culture transformed to produce the protein. One recovery process involves first reducing the ionic strength of the culture medium prior to disruption to a level effective in preventing reaggregation of cellular debris with refractile material after disruption, disrupting the desalted culture, optionally adding material to the disruptate to create a density or viscosity gradient and separating the refractile material from the cellular debris by high-speed centrifugation. Preferably the salt removal step is carried out by diafiltration and the heterologous protein comprises recombinant M-CSF, IL-2 or IFN-.beta..Type: GrantFiled: November 25, 1991Date of Patent: September 28, 1993Assignee: Cetus Oncology CorporationInventor: Glenn Dorin
-
Patent number: 4894334Abstract: A method for improving the yield of heterologous protein such as ricin A toxin, produced by recombinant bacteria by supplementing the nutrient medium in which the bacteria are grown with an ethanol and/or amino acid mixture during the terminal phase of the cultivation. Also disclosed is a method for improving the yield of heterologous proteins under the control of the PL promoter.Type: GrantFiled: April 6, 1987Date of Patent: January 16, 1990Assignee: Cetus CorporationInventors: Arie Ben-Bassat, Glenn Dorin, Keith Bauer
-
Patent number: 4894439Abstract: A process is disclosed for the purification of recombinantly produced biologically active proteins in which a solution containing a mixture of materials, including the biologically active protein, is passed through a continuous porous hydrophobic membrane, and the fraction enriched in the biologically active protein is recovered. Hydrophobic proteins such as TNF and recombinant ricin toxin A chain may be purified according to the process. Conditions for enhanced recovery of purified TNF using the process are disclosed. A highly purified TNF comprising 95% or greater TNF as determined by SDS-PAGE analysis, with an endotoxin content of less than 0.1 ng/mg TNF which is substantially free of pyrogens by the USP rabbit pyrogen test at a dosage range of 1.0 to 2.4.times.10.sup.5 U/kg, is obtained.Type: GrantFiled: May 22, 1986Date of Patent: January 16, 1990Assignee: Cetus CorporationInventors: Glenn Dorin, Wolfgang H. Hanisch, James W. Thomson, Sidney N. Wolfe, Leo S. Lin
-
Patent number: 4748234Abstract: A refractile material containing a heterologous protein is recovered from a host microorganism cell culture transformed to produce the protein. One recovery process involves disrupting the cell wall and membrane of the host cell, removing greater than 99% by weight of the salts from the disruptate, redisrupting the desalted disruptate, adding a material to the disruptate to create a density or viscosity gradient in the liquid within the disruptate, and separating the refractile material from the cellular debris by high-speed centrifugation. Another version of such a recovery process comprises the further steps of solubilizing the refractile material under reducing conditions, organically extracting the solubilized refractile material, and isolating said refractile material from the extractant.Preferably the protein is recombinant IL-2 or IFN-.beta. and the salt removal step is carried out by diafiltration.Type: GrantFiled: March 25, 1986Date of Patent: May 31, 1988Assignee: Cetus CorporationInventors: Glenn Dorin, Wolfgang H. Hanisch, Leo S. Lin
-
Patent number: 4656132Abstract: A method for improving the yield of heterologous protein such as IFN-.alpha., IFN-.beta., and IL-2, produced by recombinant bacteria by supplementing the nutrient medium in which the bacteria are grown with a water soluble alcohol and/or amino acid mixture during the terminal phase of the cultivation.Type: GrantFiled: March 28, 1984Date of Patent: April 7, 1987Assignee: Cetus CorporationInventors: Arie Ben-Bassat, Glenn Dorin, Keith Bauer, Leo Lin